Skip to main content
UNION KOREA PHARM CO.,Ltd logo

UNION KOREA PHARM CO.,Ltd — Investor Relations & Filings

Ticker · 080720 ISIN · KR7080720006 KO Manufacturing
Filings indexed 431 across all filing types
Latest filing 2026-02-23 Regulatory Filings
Country KR South Korea
Listing KO 080720

About UNION KOREA PHARM CO.,Ltd

https://ukp.co.kr/

UNION KOREA PHARM CO.,Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of prescription drugs. The company produces a range of specialty medicines in various formulations, including solid dosage forms, liquid injections, and powders. Its product portfolio addresses therapeutic areas such as neoplasms, immune system diseases, anti-inflammatory analgesics, antibiotics, and skeletal muscle relaxants. The company emphasizes strict quality control throughout the entire production cycle, from raw materials to shipping, to ensure its products meet Good Manufacturing Practice (GMP) standards. It operates in both domestic and international markets.

Recent filings

Filing Released Lang Actions
기타시장안내 (상장폐지사유 추가 우려 및 관리종목 지정사유 추가 우려 안내)
Regulatory Filings Classification · 95% confidence The document is a regulatory notice issued by the Korea Exchange regarding Korea Union Pharm. It explicitly discusses the risk of delisting and the designation of administrative issues due to capital impairment. Since this is a regulatory announcement regarding the status of the company's listing and potential delisting risks, it falls under the general regulatory filing category.
2026-02-23 Korean
기타시장안내 (개선기간 종료에 따른 상장폐지 여부 결정 안내)
Delisting Announcement Classification · 95% confidence The document is a short regulatory notice from the Korea Exchange regarding the status of Korea Union Pharm's listing, specifically concerning the end of an improvement period and the upcoming decision on potential delisting. Since it is a regulatory announcement regarding listing status and not a formal delisting notice itself, it falls under the general regulatory filing category.
2026-02-09 Korean
[기재정정]회생절차개시결정
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Rehabilitation Procedure Commencement Decision' (회생절차개시결정) for Korea Union Pharmaceutical. It details a correction (amendment) to a previous filing concerning the extension of the deadline for submitting a rehabilitation plan. Since this document pertains to legal proceedings and court-ordered rehabilitation, it falls under the category of legal matters/regulatory actions. Given the specific nature of the filing, 'LTR' (Legal Proceedings Report) is the most appropriate classification.
2026-02-05 Korean
[기재정정]회생절차개시결정
Legal Proceedings Report Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Rehabilitation Procedure Commencement Decision' (회생절차개시결정) for Korea Union Pharmaceutical. It specifically details a correction (정정신고) to a previous filing, updating the deadline for the submission of the rehabilitation plan. Since this relates to legal/regulatory proceedings regarding the company's insolvency and restructuring, and does not fit into specific categories like M&A or financial reports, it is classified as a Legal Proceedings Report (LTR).
2026-01-13 Korean
투자판단관련주요경영사항 (회생회사 한국유니온제약(주) 인수 M&A 최종 인수자 선정)
M&A Activity Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the selection of a final acquirer for a company undergoing rehabilitation (M&A). The content explicitly details the M&A process, the selection of the preferred bidder (Bukwang Pharmaceutical), and the terms of the investment agreement. This falls directly under M&A activity.
2026-01-05 Korean
기타경영사항(자율공시) (회생회사 한국유니온제약 주식회사 M&A 공고)
M&A Activity Classification · 100% confidence The document is an official announcement regarding the M&A process for a company currently under rehabilitation (회생회사). It details the sale method, bidding process, and specific timelines for submitting letters of intent and bids. This falls directly under M&A activity (TAR) as it pertains to the sale and takeover process of the company.
2025-12-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.